23/09/25 | PharmaVentures Podcasts
In this podcast, PharmaVentures explores the recent changes in the landscape of Drug Pricing. This episode delves into the evolving differences between Europe and the US and how it has an impact on both. It also assesses the how Direct-to-Patient strategies, now being deployed by pharmaceutical companies in the US, can change the cost to the patient.
Listen here:
About the Presenter:
Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.
During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.
About the Interviewee:
Samara Ferguson is Vice President at PharmaVentures, leading its Pricing and Market Access division, supporting companies in their sell-side, buy-side, and licensing due diligence and deal-making.
For over 20 years, Samara has held multiple roles in the pharmaceutical industry, giving her a unique insight and experience in market access, health economics and outcomes research. Samara’s consultancy experience also brings many years of insight across numerous therapy areas, where she rigorously pressure-tested market access and price potential, developed market access strategies, evidence generation plans, and bespoke real-world studies. Samara holds a MSc in Health Economics and Health Policy from the University of Birmingham.